Urgent.News

What's breaking now, across thousands of outlets.

Business

Invest: Morgan Stanley strategist: "Profits can't always grow that strongly"

Jim Caron speaks on the podcast about a future with lower growth rates and explains why he is optimistic for 2027 nonetheless.

Translated from German Read in German

Invest: Morgan Stanley strategist: "Profits can't always grow that strongly"

Jim Caron, the chief investment officer of Morgan Stanley's Solutions Group, recently shared his outlook on the stock market in a podcast episode from Handelsblatt Invest. The market expert notes that the current phase of the stock market requires investors to be cautious yet optimistic for the upcoming year. Caron emphasizes that investors should prepare for a future with lower growth rates, both in the US economy and corporate profits.

He warns that the gains of companies in the S&P 500 may not continue to skyrocket as they have in recent quarters, with growth rates likely to fall from 30 to 50 percent. Caron predicts that corporate earnings in the S&P 500 will rise by about 12 percent in the coming year, which is still historically strong. However, he advises investors to lower their expectations.

Caron also discusses the impact of mid-term elections on the markets and expresses no concerns about a new euro crisis, despite the turbulence in France. Listen to the full podcast through a Handelsblatt subscription for professional investors and ambitious private investors.

Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at handelsblatt.com →

More in Business

GC Cell Presents GCC2005 Phase 1a Progress

GC Cell has shared clinical progress on 'GCC2005,' an allogeneic CAR-NK cell therapy it is developing for the treatment of refractory T-cell lymphoma, on the international stage.The company said it…

  • GC Cell presented Phase 1a interim results for GCC2005 at Eastern Breeze Symposium in October 2026
  • Symposium marked 20th anniversary of Lymphoma Working Party of Korean Society of Hematology
  • GC Cell conducting domestic Phase 1b trial to expedite commercialization of GCC2005

More from Wednesday 28 October →